journal article·2025-10-14

Flower-Shaped Lipid Nanoparticles Evade Apolipoprotein E-Mediated Liver Tropism for Safe and Enhanced Cytokine-Based Cancer Immunotherapy

Yiming Qi, Yuli Fu, Xueer Wu, Ziyan Chen, Yuepeng Tang, Hoitong Ao, Haichao Zhu, Chenming Zou, Bixi Sun, Chaozhu Zheng, Zhaozhong Wang, Jingwen Hou, Yuxin Shi, Zhu Jin, Feihu Wang, Shengrong Guo

ACS Nano· Volume 19· Issue 40
Publisher page

Abstract

Lipid nanoparticles (LNPs) are effective carriers for intratumoral delivery of cytokine-encoding mRNA, but their clinical use is limited by apolipoprotein E (ApoE)-mediated hepatic tropism, which causes off-target cytokine expression and hepatotoxicity. Here, we reprogrammed LNP morphology by partially substituting native cholesterol with a TLR7/8 agonist-conjugated analog (R-Chol), generating flower-shaped LNPs (RLNPs) with reduced ApoE adsorption. Upon intratumoral injection, RLNPs maintained efficient tumor transfection while markedly decreasing liver accumulation and IL-12 mRNA-induced hepatotoxicity. Hydrodynamic modeling indicated that the distinct surface curvature of RLNPs constrained ApoE binding. RLNPs were further functionalized with CD47-SIRPα blocking peptide (IL-12 mRNA@CRLNPs), eliciting potent M1 macrophage-driven immune activation in orthotopic 4T1 tumors. When embedded in a photo-cross-linkable hydrogel (mCRLNP@HAMA gel) and combined with αPD-L1, this platform achieved sustained postoperative delivery, thereby preventing tumor recurrence and ensuring prolonged systemic safety. These findings highlight cholesterol structural tuning as a strategy to control LNP morphology and biodistribution, advancing safe and translational cytokine-based cancer immunotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Phagocytosis and Immune Regulation · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shanghai Key Laboratory of Molecular Engineering of Chiral Drugs, School of Pharmacy

Shanghai Jiao Tong University

Rehabilitation Department, Yancheng No. 1 People’s Hospital, Affiliated Hospital of Medical School, Nanjing University

Instrumental Analysis Center

Department of Anesthesiology

Zhongshan Hospital, Fudan University

School of Biomedical Engineering

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · 2024 Medical Research Projects of Yancheng Health Commission · Medicine Engineering joint foundation of Shanghai Jiao Tong University · Key project at central government level: The ability establishment of sustainable use for valuable Chinese medicine resources

References (56)

Show source-provided references
1. 10.1038/s41573-021-00283-510.1038/s41573-021-00283-5 ↗
2. 10.1021/acsnano.1c0499610.1021/acsnano.1c04996 ↗
3. 10.1038/s41587-019-0247-310.1038/s41587-019-0247-3 ↗
4. 10.1016/j.bsheal.2022.06.00110.1016/j.bsheal.2022.06.001 ↗
5. 10.1038/s41392-022-01007-w10.1038/s41392-022-01007-w ↗
6. 10.1186/s12943-021-01335-510.1186/s12943-021-01335-5 ↗
7. 10.1021/acsnano.3c0673310.1021/acsnano.3c06733 ↗
8. 10.1038/s43018-025-00950-110.1038/s43018-025-00950-1 ↗
9. 10.1016/j.jconrel.2022.03.02110.1016/j.jconrel.2022.03.021 ↗
10. 10.1038/s41571-023-00811-910.1038/s41571-023-00811-9 ↗
11. 10.1158/1078-0432.CCR-20-047210.1158/1078-0432.CCR-20-0472 ↗
12. 10.1016/j.jconrel.2025.11358810.1016/j.jconrel.2025.113588 ↗
13. 10.1126/scitranslmed.adm845110.1126/scitranslmed.adm8451 ↗
14. 10.1200/JCO.2012.46.365310.1200/JCO.2012.46.3653 ↗
15. 10.1038/s41563-019-0566-210.1038/s41563-019-0566-2 ↗
16. 10.1126/sciadv.abf439810.1126/sciadv.abf4398 ↗
17. 10.1016/j.pathol.2018.11.00210.1016/j.pathol.2018.11.002 ↗
18. 10.1016/j.isci.2021.10347910.1016/j.isci.2021.103479 ↗
19. 10.1126/science.aay363810.1126/science.aay3638 ↗
20. 10.1073/pnas.210925611810.1073/pnas.2109256118 ↗
21. 10.1016/j.jconrel.2024.10.02810.1016/j.jconrel.2024.10.028 ↗
22. 10.1016/j.ymthe.2018.03.01010.1016/j.ymthe.2018.03.010 ↗
23. 10.1016/j.ijpharm.2021.12058610.1016/j.ijpharm.2021.120586 ↗
24. 10.1038/s41565-018-0319-410.1038/s41565-018-0319-4 ↗
25. 10.1016/j.addr.2016.03.00810.1016/j.addr.2016.03.008 ↗
26. 10.1016/j.bbagen.2011.07.01610.1016/j.bbagen.2011.07.016 ↗
27. 10.1021/acsnano.4c1656210.1021/acsnano.4c16562 ↗
28. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
29. 10.1016/j.biomaterials.2011.02.04510.1016/j.biomaterials.2011.02.045 ↗
30. 10.1016/j.jconrel.2019.01.00110.1016/j.jconrel.2019.01.001 ↗
31. 10.1021/acsnano.4c0636910.1021/acsnano.4c06369 ↗
32. 10.1021/acsnano.8b0364010.1021/acsnano.8b03640 ↗
33. 10.1038/s41467-020-14527-210.1038/s41467-020-14527-2 ↗
34. 10.1016/j.jconrel.2024.11.07310.1016/j.jconrel.2024.11.073 ↗
35. 10.1038/s41467-025-61114-410.1038/s41467-025-61114-4 ↗
36. 10.1021/acs.chemrev.5b0004610.1021/acs.chemrev.5b00046 ↗
37. 10.1021/ar500260t10.1021/ar500260t ↗
38. 10.1016/S0006-3495(99)77369-810.1016/S0006-3495(99)77369-8 ↗
39. 10.1038/nri100110.1038/nri1001 ↗
40. 10.1038/nrgastro.2010.21310.1038/nrgastro.2010.213 ↗
41. 10.1016/j.bsheal.2024.07.00510.1016/j.bsheal.2024.07.005 ↗
42. 10.1021/acsnano.0c1006410.1021/acsnano.0c10064 ↗
43. 10.1016/j.jconrel.2023.07.03510.1016/j.jconrel.2023.07.035 ↗
44. 10.1016/j.nantod.2022.10170210.1016/j.nantod.2022.101702 ↗
45. 10.1021/acsami.4c0983010.1021/acsami.4c09830 ↗
46. 10.1002/adma.20220878210.1002/adma.202208782 ↗
47. 10.1016/j.cell.2009.05.04510.1016/j.cell.2009.05.045 ↗
48. 10.1146/annurev-immunol-032713-12014210.1146/annurev-immunol-032713-120142 ↗
49. 10.1126/science.123885610.1126/science.1238856 ↗
50. 10.1002/cam4.376810.1002/cam4.3768 ↗
51. 10.1016/bs.acr.2019.03.00610.1016/bs.acr.2019.03.006 ↗
52. 10.1021/acsnano.4c0844810.1021/acsnano.4c08448 ↗
53. 10.1158/1078-0432.CCR-06-304510.1158/1078-0432.CCR-06-3045 ↗
54. 10.1126/scitranslmed.aan346410.1126/scitranslmed.aan3464 ↗
55. 10.1016/j.bsheal.2022.03.00210.1016/j.bsheal.2022.03.002 ↗
56. 10.1038/s41551-020-0597-710.1038/s41551-020-0597-7 ↗